bladder cancer

Deal terminate tear up end deal scrap

Biotech

UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data

UroGen is handing back an anti-CTLA-4 antibody after concluding that phase 1 data for the bladder cancer drug didn’t warrant further development.

James Waldron Nov 6, 2025 10:00am

Tecentriq

Fierce Pharma

Roche touts Tecentriq biomarker win in bladder cancer

Aug 18, 2025 4:17pm

White arrow on a road pointing to the rising sun

Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3

Apr 28, 2025 7:25am

cancer target detection radiopharma radio

Acrivon stops testing Lilly castoff for ovarian, bladder cancer

Mar 26, 2025 7:05am

Soccer ball flying into a net scoring a goal

Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study

Jan 10, 2025 6:45am

gold arrow pointing upward forward

Protara shares spike after bladder cancer data drop

Dec 5, 2024 2:30pm